Efficacy of MiniMed™ 780G® on glucose management, sleep quality, and psychological aspects in persons with type 1 diabetes treated with MiniMed™ 770G®: A 3-month prospective single-center observational study.

AIMS/INTRODUCTION: The MiniMed™ 780G® is effective for improving glycemic control; however, few studies have specifically examined the impact of upgrading from MiniMed™ 770G® to MiniMed™ 780G® in adults. We determined the effects of upgrading from MiniMed™ 770G® to MiniMed™ 780G® (780G) on glucose management, psychological distress, daily life quality, and sleep in type 1 diabetes mellitus (T1DM). MATERIALS AND METHODS: In this single-center prospective study, we observed 21 adults who transitioned from the MiniMed™ 770G® to the 780G for 3 months. Glycemic outcomes, insulin delivery parameters, frequency of alarms, and sensor calibrations were assessed. Patient-reported outcomes were evaluated using the Problem Areas in Diabetes (PAID), the Diabetes Treatment Satisfaction Questionnaire status version, the Diabetes Therapy-Related Quality of Life, and the Pittsburgh Sleep Quality Index. RESULTS: Glycated hemoglobin (HbA1c) decreased (7.5 ± 1.3%-7.0 ± 0.8%, mean difference: -0.5%, 95% Confidence Interval (CI): -0.9 to -0.1; P = 0.018). Time in tight range (TITR) showed trends toward improvement (44.9 ± 15.5%-48.9 ± 15.5%, mean difference: 4.0%, 95% CI: -0.7 to 8.6; P = 0.090). Alarm frequency declined (11.9 ± 8.7-7.1 ± 5.5 times/day, mean difference: -4.8, 95% CI: -7.0 to -2.6; P = 0.0002), and calibration frequency decreased (3.6 ± 2.2-0.8 ± 0.6 times/day, mean difference: -2.8, 95% CI: -3.7 to -1.9; P < 0.0001). The PAID score improved, decreasing from 38.7 ± 19.9 to 31.7 ± 19.3 (mean difference: -7.0, 95% CI: -14.7 to 0.7; P = 0.074). CONCLUSIONS: Favorable changes in HbA1c, TITR, and PAID scores suggest potential glycemic and psychological benefits.